Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Evotec SE
  6. News
  7. Summary
    EVT   DE0005664809

EVOTEC SE

(EVT)
  Report
Delayed Quote. Delayed Xetra - 01/21 11:35:08 am
35.83 EUR   -4.20%
01/20EVOTEC : Upgraded to Buy by Berenberg
MD
01/18EVOTEC : partner Celmatix achieves milestone for PCOS drug programme
PU
01/18EVOTEC : RBC remains its Buy rating
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

EVOTEC : Receives a Buy rating from RBC

11/29/2021 | 05:29am EST

RBC analyst Zoe Karamanoli maintains his Buy rating on the stock. The target price has been revised upwards and is now set at EUR 50, compared with EUR 39 previously.


ę MarketScreener with dpa-AFX Analyser 2021
All news about EVOTEC SE
01/20EVOTEC : Upgraded to Buy by Berenberg
MD
01/18EVOTEC : partner Celmatix achieves milestone for PCOS drug programme
PU
01/18EVOTEC : RBC remains its Buy rating
MD
01/18Evotec, Eli Lilly to Collaborate on Treatments for Metabolic Diseases
MT
01/18Evotec, Eli Lilly to Address Kidney Diseases, Diabetes in Three-Year Drug Discovery Col..
MT
01/18Eli Lilly, Evotec Team Up to Discover Drugs For Metabolic Diseases
MT
01/18Evotec and Lilly enter into drug discovery collaboration in metabolic diseases
EQ
01/11Evotec, Bristol Myers Expand Neurogenerative Partnership to Include New Targeted Protei..
MT
01/11Evotec, Bristol Myers Squibb Expand Team-Up to Cover New Alzheimer's Treatment Approach
MT
01/11EVOTEC : expands neuroscience collaboration with Bristol Myers Squibb to include new targe..
PU
More news
Analyst Recommendations on EVOTEC SE
More recommendations
Financials
Sales 2021 580 M 658 M 658 M
Net income 2021 239 M 272 M 272 M
Net cash 2021 473 M 537 M 537 M
P/E ratio 2021 25,1x
Yield 2021 -
Capitalization 6 276 M 7 118 M 7 119 M
EV / Sales 2021 10,0x
EV / Sales 2022 8,87x
Nbr of Employees 4 081
Free-Float -
Chart EVOTEC SE
Duration : Period :
Evotec SE Technical Analysis Chart | EVT | DE0005664809 | MarketScreener
Technical analysis trends EVOTEC SE
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 35,83 €
Average target price 45,10 €
Spread / Average Target 25,9%
EPS Revisions
Managers and Directors
Werner Lanthaler Chief Executive Officer
Enno Spillner Chief Financial Officer
Iris L÷w-Friedrich Chairman-Supervisory Board
Cord E. Dohrmann Chief Scientific Officer
Craig L. Johnstone Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
EVOTEC SE-15.69%7 118
MODERNA, INC.-36.98%64 900
LONZA GROUP AG-15.65%52 307
IQVIA HOLDINGS INC.-14.60%46 031
SEAGEN INC.-17.50%23 323
ICON PUBLIC LIMITED COMPANY-18.65%20 508